Pseudotyped Viruses and Surrogate Neutralization Assays

This direction is merged into another direction: pseudovirus neutralization assay. Its last version stays readable and citable here.

Version 1 of 129 papers30 conceptsfrozen 2026-10-04

To study a highly pathogenic virus like SARS-CoV-2, Lassa, or Hantaan, researchers typically require high-containment Biosafety Level 3 or 4 (BSL-3/4) laboratories. These facilities are expensive, rare, and require rigorous safety protocols that slow down the pace of discovery. To bypass these bottlenecks, researchers have developed "surrogate" systems that decouple the dangerous parts of a virus (its ability to replicate and cause disease) from the parts we need to study (how it enters cells and how antibodies block it).

The Anatomy of a Pseudotyped Virus

The most powerful tool in this repertoire is the pseudotyped virus. Think of a virus as a combination of a "payload" (the genetic instructions to replicate) and a "key" (the surface proteins that unlock a host cell).

In a pseudotyped system, researchers take a safe, non-replicating "backbone"—often derived from a Lentivirus, HIV-1, or Vesicular Stomatitis Virus (VSV)—and engineer it to display the "keys" of a dangerous pathogen on its surface. For example, Haojie Wang and colleagues developed a system for Transmissible Gastroenteritis Virus (TGEV) by swapping the native envelope of a safe vector with the TGEV spike protein in Establishment of a pseudovirus neutralization assay for TGEV.

When this chimeric virus "infects" a cell, it doesn't produce more virus. Instead, it delivers a reporter gene—like Green Fluorescent Protein (GFP) or Luciferase—that causes the cell to glow. This provides a clear, quantifiable signal: if the cell glows, the "key" worked, and the virus entered.

Measuring Immunity Without the Pathogen

This mechanism is the foundation of the Pseudovirus Neutralization Assay (pNA). To test how well a patient's blood can fight a virus, researchers mix the patient's serum with these pseudotyped particles. If the antibodies in the serum are effective, they will coat the viral "keys," preventing them from unlocking the cell.

As David C. Montefiori and Dean Follmann demonstrated in Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration, this allows for a precise, standardized measurement of neutralizing antibody (nAb) titers across different vaccine platforms and monoclonal treatments. Because these particles are non-infectious, these tests can be performed in standard BSL-2 labs, enabling large-scale studies like the antenatal screening led by Sheila Lumley in SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort.

Surrogate Assays: The Biochemical Handshake

While pseudoviruses mimic the process of entry, surrogate neutralization assays (sVNT) simplify the problem even further into a biochemical "handshake."

Instead of using a virus-like particle, these assays measure the physical binding between a purified viral protein (like the SARS-CoV-2 Receptor Binding Domain) and its human receptor (like ACE2). Katharina Röltgen used this high-throughput competitive assay to show that antibody levels decline rapidly in mild COVID-19 cases in SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness.

These assays are purely biochemical—no live cells or viruses are required. This makes them ideal for rapid diagnostic kits and large epidemiological cohorts, such as the Munich study evaluated by Laura Olbrich and Noemi Castelletti in A Serology Strategy for Epidemiological Studies.

Applications in Drug Discovery and Evolution

Beyond measuring immunity, these surrogate systems allow researchers to safely "interrogate" the virus:

  1. Drug Screening: Changzhi Li and Hong Zhang used pseudotyped viruses to screen thousands of compounds, identifying TS-984 as a potent entry inhibitor in Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2.
  2. Mapping Mutations: In Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex, Caleb R. Carr and Katharine H. D. Crawford used pseudotyping to test how every possible mutation in the Lassa virus affects its ability to enter cells and evade antibodies.
  3. Variant Tracking: As new variants like Omicron JN.1 emerge, researchers like Haijun Tang use VSV-based pseudotypes to immediately quantify how much better these strains are at escaping existing immunity, as seen in Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant.

By reducing a complex, dangerous pathogen to a measurable biochemical interaction or a glowing reporter signal, these surrogate systems have transformed virology from a high-risk, specialized field into a high-throughput, accessible science.

Papers in this version

History & citationVersion 1 · 2026-10-04

Merged into another direction · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_pseudotyped_viruses_and_surrogate_neutra_3a6dfbd8,
  title = {Pseudotyped Viruses and Surrogate Neutralization Assays},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/pseudotyped-viruses-and-surrogate-neutralization-assays/rdr_3a6dfbd8d5944fcd84a04a803fdc7d14},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_pseudotyped_viruses_and_surrogate_neutra_3a6dfbd8_v1,
  title = {Pseudotyped Viruses and Surrogate Neutralization Assays},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/pseudotyped-viruses-and-surrogate-neutralization-assays/rdr_3a6dfbd8d5944fcd84a04a803fdc7d14/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}